Anticancer Bioscience

Executive Summary

Anticancer Bioscience is a preclinical-stage oncology biotech based in Chengdu, China, leveraging genetics and genomics to develop targeted cancer therapies via synthetic lethal approaches. Founded in 2016, the company focuses on identifying genetic vulnerabilities unique to cancer cells and translating these insights into novel drug candidates. Synthetic lethality offers a promising strategy to selectively kill tumor cells while sparing normal tissue, potentially addressing high unmet needs in oncology. The company's pipeline appears to be in early preclinical development, with no disclosed lead compounds or funding history. Given the increasing interest in precision oncology and synthetic lethality (e.g., PARP inhibitors), Anticancer Bioscience occupies a potentially valuable niche, though significant technical and clinical risks remain. Its success will depend on advancing candidates into IND-enabling studies and securing partnerships or financing to support clinical development.

Upcoming Catalysts (preview)

• Q2 2027Completion of IND-enabling studies for lead synthetic lethal candidate40% success
• Q4 2026Presentation of preclinical efficacy data at a major oncology conference60% success
• Q3 2026Series A funding round or strategic partnership announcement35% success